Search clinical trials

Name a drug, target, or condition and Anara searches ClinicalTrials.gov, PubMed, and bioRxiv together, then summarizes what is in development, what has reported, and what is worth attention. Use it before a portfolio decision, competitive review, or due diligence call.

Prompt

A clinical pharmacologist assesses the competitive landscape for a new indication of an existing drug.

Pull the latest clinical trial data on GLP-1 receptor agonists for non-alcoholic steatohepatitis from PubMed, bioRxiv, and ClinicalTrials.gov. I want to know: which trials are currently recruiting or active, what phases they are in, who the sponsors are, what the primary endpoints are, and where published efficacy or safety data already exists. Summarize what is worth paying attention to and flag any trials that have reported preliminary results in the last 12 months.

What to add to your library

• Required: nothing to upload. The prompt carries it and Anara searches the live databases.
• Optional: a date range, such as "trials registered or updated since January 2024."
• Optional: specific phases ("Phase 2 and Phase 3 only") or a comparator or mechanism of action.

What you get

• A summary organized by state: trials with published results, trials in active stages, and trials in early or planning phases.
• For each trial: NCT identifier, sponsor, status, phase, primary endpoint, and a link to the ClinicalTrials.gov record.
• Links to any PubMed or bioRxiv paper tied to a trial.

Follow-ups

Go deeper on one trial.

Go deeper on the semaglutide NASH trial that appeared in the results. What were the primary and secondary endpoints as registered? Has anything been published on interim data? Who is running the trial and what is the estimated completion date?

Compare trial designs across sponsors.

Compare the primary endpoint designs across the four active NASH trials you identified. How are sponsors defining the primary outcome: liver biopsy-confirmed resolution, non-invasive biomarker improvement, or something else? Where do the approaches diverge?

Tips

• Name all three sources explicitly. Otherwise Anara may default to the general academic index and not prioritize registry data.
• For large indications, add filters: phase, status, date range, or "sponsored by [company]."
• Registry records lag when sponsors are slow to update. If a trial looks inactive but you have seen recent data, check its registry entry directly.
• Save the summary as a note and periodically ask Anara to check for updates since its date.